JW Asset Management portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 7, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
JW Asset Management reported a $320M portfolio of 21 positions to the SEC as of the end of Q2 2026. Its largest positions are ESTA, SNDK, COCO. During the quarter it opened Travere Therapeutics and exited Alphabet and Meta Platforms.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then JW Asset Management has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
Stake reported in the company · event of Jun 30, 2026 · filed Jul 31, 2026 · filing ↗
What changed this quarter
16 positions with a change (5 new, 2 added to, 6 trimmed, 3 sold). 5 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Establishment Labs Holdings−12%fewer sharesReduced71.4% → 72.2%
- Alphabet−2.5 ppof portfolioSold out3.2% → —
- Meta Platforms−1.6 ppof portfolioSold out2.0% → —
- Sandisk+20%more sharesIncreased1.7% → 5.6%
- Travere Therapeutics+0.5 ppof portfolioNew— → 0.5%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Establishment Labs HoldingsESTA72.2%
- SandiskSNDK5.6%
- Vita CocoCOCO4.5%
- Catalyst Pharmaceuticals3.8%
- Micron TechnologyMU2.5%
- IRENIREN2.1%
- Idaho Strategic ResourcesIDR1.4%
- Ralph LaurenRL1.3%
- CAVA GroupCAVA1.2%
- NVIDIANVDA1.0%
- On HoldingONON0.8%
- Five BelowFIVE0.6%
- Travere TherapeuticsTVTX0.5%
- Heron TherapeuticsHRTX0.5%
- Dell TechnologiesDELL0.5%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 78%
- ● Information Technology 12%
- ● Consumer Staples 5%
- ● Consumer Discretionary 4%
- ● Materials 1%
How its portfolio changed (8 quarters)
Q2 2026: 21
Q2 2026: 96%
Q2 2026: 8.8%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Mar 20, 2026 (high confidence).
The data, as reported: JW ASSET MANAGEMENT, LLC (CRD 160805): 7.B private funds: 4 hedge (gross assets $477M); 5.D assets by client type: pooled vehicles 100% (of $477M) · 13F: 74% of the portfolio was already held when the stock started trading
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Dalal StreetInvestment firm · $327M
- MuhlenkampInvestment firm · $345M
- Matthew 25 ManagementInvestment firm · $345M
- Stonehill Capital ManagementInvestment firm · $350M
- SW Investment ManagementInvestment firm · $352M
- INCA InvestmentsInvestment firm · $353M